Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxWages, Salaries and Other
Others
Ratios

Greater Cannabis Company (GCAN) EBITDA (2017 - 2022)

Greater Cannabis Company's EBITDA history spans 6 years, with the latest figure at -$42267.0 for Q4 2022.

  • For Q4 2022, EBITDA rose 64.81% year-over-year to -$42267.0; the TTM value through Dec 2022 reached -$177035.0, up 48.41%, while the annual FY2025 figure was -$183005.0, 17.1% down from the prior year.
  • EBITDA reached -$42267.0 in Q4 2022 per GCAN's latest filing, up from -$49304.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $72562.0 in Q1 2018 to a low of -$200627.0 in Q3 2018.
  • Average EBITDA over 5 years is -$76094.0, with a median of -$75253.0 recorded in 2018.
  • Peak YoY movement for EBITDA: skyrocketed 170.02% in 2018, then tumbled 830.83% in 2019.
  • A 5-year view of EBITDA shows it stood at -$76168.0 in 2018, then crashed by 155.66% to -$194730.0 in 2019, then surged by 72.51% to -$53532.0 in 2020, then crashed by 124.36% to -$120102.0 in 2021, then surged by 64.81% to -$42267.0 in 2022.
  • Per Business Quant, the three most recent readings for GCAN's EBITDA are -$42267.0 (Q4 2022), -$49304.0 (Q3 2022), and -$43034.0 (Q2 2022).